Syndax Pharmaceuticals, Inc. (SNDX) — Analyst outlook / Analyst consensus target is. Based on 22 analyst ratings, the consensus is bullish — 20 Buy, 2 Hold.
The consensus price target is $39.33 (low: $35.00, high: $45.00), representing an upside of 61% from the current price $24.43.
Analysts estimate Earnings Per Share (EPS) of $-3.48 and revenue of $0.05B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.73 vs est $-3.48 (missed -7.3%). 2025: actual $-3.30 vs est $-3.10 (missed -6.4%). Analyst accuracy: 94%.
SNDX Stock — 12-Month Price Forecast
$39.33
▲ +60.99% Upside
Average Price Target
Based on 22 Wall Street analysts offering 12-month price targets for Syndax Pharmaceuticals, Inc., the average price target is $39.33, with a high forecast of $45.00, and a low forecast of $35.00.
The average price target represents a +60.99% change from the last price of $24.43.
Highest Price Target
$45.00
Average Price Target
$39.33
Lowest Price Target
$35.00
SNDX Analyst Ratings
Buy
Based on 22 analysts giving stock ratings to Syndax Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — SNDX
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.73
vs Est –$3.48
▼ 6.8% off
2025
Actual –$3.30
vs Est –$3.10
▼ 6.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — SNDX
47%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.024B
vs Est $0.048B
▼ 103.9% off
2025
Actual $0.172B
vs Est $0.168B
▲ 2.4% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
